WEBINAR: Gunderson Dettmer Hosts Tackling the Lifecycle of Affinivax: From Inception to Exit

Insights October 18, 2022

Gunderson Dettmer hosted the Tackling the Lifecycle of Affinivax: From Inception to Exit webinar to discuss Affinivax's trajectory from an early-stage vaccine start-up to its \$3.3 billion acquisition by GSK. Gunderson Dettmer partner Tim Ehrlich, Affinivax CEO Steve Brugger, Affinivax Chief Business Officer Stuart Chaffee, and J.P. Morgan Global Chairman Philip Ross led the webinar and shared insights about Affinivax's acquisition.

Discussion topics from this event include

- Initial fundraising
- Strategic partnering strategy
- Scaling the business with growth equity/IPO
- Reacquiring a program from a partner
- Managing a clinical-stage asset
- Staying independent vs. selling
- Selling the business

To watch the webinar video, click here.

Companies Affinivax GSK

Related People



Timothy H. Ehrlich PARTNER P +1 617 648 9399

Related Services

Mergers & Acquisitions

Featured Insights

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in "Where the legal battle stands around copyright and AI training"

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding

INSIGHTS

Legal 500 Country Comparative Guides 2025: Venture Capital (Singapore)